-
RemeGen’s 2024 Revenue Soars 58.54% on Strong Product Sales and R&D Growth
•
China-based biotech RemeGen Co., Ltd (HKG: 9995, SHA: 688331) released its 2024 financial report, recording RMB 1.717 billion (USD 236.3 million) in revenues, a 58.54% year-on-year (YOY) increase. Product sales reached RMB 1.699 billion (USD 233.9 million), up 61.9% YOY. The annual loss decreased by 2.8% YOY to RMB 1.468…
-
Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab
•
Alphamab Oncology (HKG: 9966) has announced its 2024 financial results, marking a significant milestone with its first annual profit. The company reported revenues of RMB 640.08 million (USD 88.1 million), representing a 192.58% year-on-year increase. Profits reached RMB 166.34 million (USD 22.9 million), driven primarily by sales of its core…
-
Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline
•
China-based Everest Medicines (HKG: 1952) has announced its 2024 financial results, marking a significant milestone in its growth trajectory. The company reported a remarkable 461% year-on-year increase in revenues, reaching RMB 707 million (USD 97 million). Concurrently, the non-IFRS net loss narrowed by 25% to RMB 537.6 million (USD 74…
-
Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals
•
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has released its 2024 financial report, recording revenues of RMB 1.933 billion (USD 266 million), representing a 25.5% year-on-year (YOY) increase. This growth includes USD 147.5 million in cooperation payments from US partner Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK), UK-based…
-
Eli Lilly Launches Lilly Gateway Laboratory in China to Boost Biotech Innovation
•
US major Eli Lilly & Co., (NYSE: LLY) has announced the opening of the Lilly Gateway Laboratory (LGL) in China. This state-of-the-art facility, the fourth of its kind globally, is equipped with first-class ready-to-use laboratories, shared meeting rooms, and convenient workstations. The laboratory is designed to support the growth of…
-
Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases
•
China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN). The collaboration centers on developing potential first-in-class macrocyclic peptides targeting chronic diseases, with AstraZeneca gaining access to Syneron Bio’s innovative Synova platform. Synova Platform and Research FocusThe…
-
Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development
•
China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN) to discover and develop next-generation multi-specific antibodies for immunology, oncology, and beyond. The collaboration grants AstraZeneca an option to license multiple programs utilizing Harbour BioMed’s proprietary Harbour Mice fully human antibody technology platform…
-
Kexing Biopharm and Hinova Forge Alliance to Expand Global Market Reach
•
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced this week a strategic alliance with compatriot firm Hinova Pharmaceuticals Inc. (SHA: 688302) to jointly explore and develop overseas markets for their collaborative products. Collaboration DetailsThe partnership between Kexing Biopharm and Hinova Pharmaceuticals is designed to leverage their combined strengths in oncology…
-
Paratek Pharmaceuticals to Acquire Optinose for $330 Million
•
Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ: OPTN) announced a definitive merger agreement on March 19, 2025. Under the terms of the agreement, Paratek will acquire Optinose, including its approved product XHANCE (fluticasone propionate), an innovative drug-device combination for the treatment of chronic rhinosinusitis (CRS) with or without nasal polyps. Transaction…
-
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth
•
China-based Harbour BioMed (HKG: 2142) announced the appointment of Michael D. Patten as Chief Strategy Officer. Based in the United States, Michael will report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. This strategic move aims to enhance Harbour BioMed’s global influence and business expansion. Role…
-
Juvensis Therapeutics Secures RMB100 Million for Heart Gene Therapy Development
•
Shanghai-based Juvensis Therapeutics, a specialist in anti-aging therapies, reportedly raised upwards of RMB100 million (USD13.8 million) via a Pre-Series A financing round. Led by Growth FoF, the funding included contributions from Nanjing Jiangbei New Area Sci-tech Investment Group, Henry WU, and Shanghai Healthcare Capital, among others. The proceeds will be…
-
Sun Pharma to Acquire Checkpoint Therapeutics for USD355 Million, Focusing on Cancer Immunotherapy
•
India-based Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) announced plans to acquire all outstanding shares of US-headquartered Checkpoint Therapeutics (NASDAQ: CKPT) for USD4.1 per share, totaling USD355 million. As part of the deal, Checkpoint shareholders will receive a contingent value right (CVR) entitling them to up to USD0.70 per share, contingent…
-
Jiangsu Nhwa Pharmaceutical Invests in NeuroThree to Develop CNS Therapies
•
China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced plans to subscribe to Hong Kong-headquartered NeuroThree Therapeutics, Inc.’s Pre-Series A financing round, investing USD 3.5 million for 12.5 million shares. Upon completion of the transaction, Nhwa will hold a 10.448% stake in NeuroThree. Company BackgroundFounded in 2021, NeuroThree focuses on…
-
Geneseeq and MGI Tech Form Global Partnership for Oncology Solutions
•
Geneseeq Technology Inc., a genetic cancer testing service provider operating in Canada and China, has entered into a global partnership with China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114). The collaboration leverages MGI’s DNBSEQ gene sequencing platform to conduct in-depth cooperation in clinical basic research, product regulatory filing…
-
Harbour BioMed Licenses HAT001/HBM9013 to Global Partner for CRH-Targeted Therapy
•
China-based Harbour BioMed (HKG: 2142) announced a strategic collaboration and licensing agreement with an undisclosed partner to advance the development of HAT001/HBM9013, a novel corticotropin releasing hormone (CRH) targeted therapy. The alliance aims to promote the drug’s development globally, excluding Greater China. Agreement DetailsUnder the agreement, the partner will hold…
-
Green Valley and Vazyme Team Up on Alzheimer’s Disease Initiatives
•
China-based Green Valley (Shanghai) Pharmaceuticals Co., Ltd. and Vazyme Biotech Co., Ltd (SHA: 688105) have entered into a strategic partnership to collaborate on the screening, diagnosis, and early intervention of Alzheimer’s disease (AD). Collaboration GoalsThe partnership will leverage the strengths of both companies to: Strategic SynergiesBy combining their expertise, Green…
-
CARsgen Therapeutics and Zhuhai SB Xinchuang Invest in UCARsgen for Allogeneic CAR-T Therapies
•
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has entered into an agreement with an investment fund managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management Enterprise (Limited Partnership) to jointly invest in its subsidiary UCARsgen Biotech Limited. UCARsgen focuses on developing allogeneic CAR-T cell therapies for hematologic malignancies. Deal Highlights
-
Dizal Pharma’s 2024 Revenues Surge 295% to RMB360M, Loss Narrows by RMB251M
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial preview, showing annual revenues jumped 294.79% year-on-year (YOY) to RMB360.4 million ($49.67 million). Net loss attributable to the parent company was RMB856.77 million ($118 million), down RMB250.94 million ($34.6 million) from 2023. Key Highlights
-
Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a licensing agreement with the University of Alabama at Birmingham (UAB) to support research in B cell development. Agreement DetailsUnder the agreement, Dr. James Kobie of UAB will receive a non-exclusive license to develop fully human…
-
Beihai Biotech Licenses Beizary to Zydus Lifesciences for US Market
•
China-based Zhuhai Beihai Biotech Co., Ltd announced a licensing agreement with Zydus Lifesciences, granting the India-headquartered firm exclusive commercialization rights to Beizary, a modified version of docetaxel, in the United States. Deal TermsUnder the agreement, Beihai will handle manufacturing and supply of Beizary. The company will receive an upfront payment…
